As Biotechnology businesses, Cortexyme Inc. (NASDAQ:CRTX) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Zynerba Pharmaceuticals Inc.||10||2943.80||N/A||-2.27||0.00|
Table 1 demonstrates Cortexyme Inc. and Zynerba Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 shows us the net margins, return on equity and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Zynerba Pharmaceuticals Inc.||0.00%||-64.1%||-54.9%|
The Current Ratio and Quick Ratio of Cortexyme Inc. are 15.9 and 15.9 respectively. Its competitor Zynerba Pharmaceuticals Inc.’s Current Ratio is 9.9 and its Quick Ratio is 9.9. Cortexyme Inc. can pay off short and long-term obligations better than Zynerba Pharmaceuticals Inc.
The table shown features the ratings and recommendations for Cortexyme Inc. and Zynerba Pharmaceuticals Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Zynerba Pharmaceuticals Inc.||0||0||1||3.00|
Meanwhile, Zynerba Pharmaceuticals Inc.’s consensus price target is $18, while its potential upside is 47.30%.
Insider & Institutional Ownership
The shares of both Cortexyme Inc. and Zynerba Pharmaceuticals Inc. are owned by institutional investors at 22.4% and 24.8% respectively. Insiders owned 2.5% of Cortexyme Inc. shares. On the other hand, insiders owned about 13.78% of Zynerba Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Zynerba Pharmaceuticals Inc.||-7.75%||-24.95%||-11.08%||110.54%||56.43%||256.57%|
For the past year Cortexyme Inc. has weaker performance than Zynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.